Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.

Infant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of mixed lineage leukemia (MLL) gene rearrangements, a poor outcome, and resistance to chemotherapeutic drugs. One exception is cytosine arabinoside (Ara-C), to which infant ALL cells are highly sensitive. To investigate the mechanism underlying Ara-C sensitivity in infants with ALL, mRNA levels of Ara-C-metabolizing enzymes were measured in infants (n = 18) and older children (noninfants) with ALL (n = 24). In the present study, infant ALL cells were 3.3-fold more sensitive to Ara-C (P =.007) and accumulated 2.3-fold more Ara-CTP (P =.011) upon exposure to Ara-C, compared with older children with ALL. Real-time quantitative reverse trancriptase-polymerase chain reaction (RT-PCR) (TaqMan) revealed that infants express 2-fold less of the Ara-C phosphorylating enzyme deoxycytidine kinase (dCK) mRNA (P =.026) but 2.5-fold more mRNA of the equilibrative nucleoside transporter 1 (hENT1), responsible for Ara-C membrane transport (P =.001). The mRNA expression of pyrimidine nucleotidase I (PN-I), cytidine deaminase (CDA), and deoxycytidylate deaminase (dCMPD) did not differ significantly between both groups. hENT1 mRNA expression inversely correlated with in vitro resistance to Ara-C (r(s) = -0.58, P =.006). The same differences concerning dCK and hENT1 mRNA expression were observed between MLL gene-rearranged (n = 14) and germ line MLL cases (n = 25). An oligonucleotide microarray screen (Affymetrix) comparing patients with MLL gene-rearranged ALL with those with nonrearranged ALL also showed a 1.9-fold lower dCK (P =.001) and a 2.7-fold higher hENT1 (P =.046) mRNA expression in patients with MLL gene-rearranged ALL. We conclude that an elevated expression of hENT1, which transports Ara-C across the cell membrane, contributes to Ara-C sensitivity in MLL gene-rearranged infant ALL.

[1]  Dan L. Longo,et al.  Cancer Chemotherapy and Biotherapy: Principles and Practice , 2001 .

[2]  J. Raemaekers,et al.  A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. , 2001, The Journal of molecular diagnostics : JMD.

[3]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[4]  D. Arthur,et al.  Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children’s Cancer Group , 1999, Leukemia.

[5]  S. Seeber,et al.  Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia , 1998, British journal of haematology.

[6]  M. D. Boer,et al.  Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.

[7]  S. Seeber,et al.  Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro. , 1998, Leukemia research.

[8]  J. Shuster,et al.  Intensive Alternating Drug Pairs After Remission Induction for Treatment of Infants With Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Pilot Study , 1998, Journal of pediatric hematology/oncology.

[9]  G. Magni,et al.  Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides , 1997, FEBS letters.

[10]  A. Paterson,et al.  Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. , 1997, Blood.

[11]  M. Volm,et al.  Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia. , 1997, Anti-cancer drugs.

[12]  S. Seeber,et al.  Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. , 1996, Leukemia.

[13]  C. A. Blau,et al.  Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. , 1996, Experimental hematology.

[14]  H. Hori,et al.  Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay. , 1996, Leukemia research.

[15]  J. Laliberté,et al.  Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside , 1996, Anti-cancer drugs.

[16]  G. Peters,et al.  Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. , 1996, Leukemia research.

[17]  M. Greaves.  Infant leukaemia biology, aetiology and treatment. , 1996, Leukemia.

[18]  C. Pui,et al.  Biology and treatment of infant leukemias. , 1995, Leukemia.

[19]  R. Pieters,et al.  Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.

[20]  J. Shuster,et al.  Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1994, Blood.

[21]  J. Downing,et al.  11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Heerema,et al.  Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. , 1994, Blood.

[23]  R. Willemze,et al.  Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. , 1993, Leukemia.

[24]  B. Mitchell,et al.  Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. , 1992, Cancer research.

[25]  R. Pieters,et al.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .

[26]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[27]  R. Pieters,et al.  Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. , 1988, Cancer letters.

[28]  J. White,et al.  Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. , 1987, The Journal of clinical investigation.

[29]  S. Sallan,et al.  Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. , 1982, Blood.

[30]  J. Wiley,et al.  Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. , 1982, The Journal of clinical investigation.

[31]  C. N. Coleman,et al.  Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. , 1975, Blood.

[32]  D. Ho,et al.  Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine , 1971 .

[33]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[34]  C. Cass,et al.  Recent advances in the molecular biology of nucleoside transporters of mammalian cells. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[35]  K. Kishi,et al.  Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. , 1998, Leukemia & lymphoma.

[36]  L. Frankel,et al.  Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). , 1997, Journal of pediatric hematology/oncology.

[37]  E. Frei,et al.  Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. , 1971, Clinical pharmacology and therapeutics.